Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

Background The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods Sixty-five patients who had nonre...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastrointestinal surgery 2013-09, Vol.17 (9), p.1609-1617
Main Authors: Kobayashi, Masanori, Sakabe, Tomoyo, Abe, Hirofumi, Tanii, Mitsugu, Takahashi, Hidenori, Chiba, Asako, Yanagida, Eri, Shibamoto, Yuta, Ogasawara, Masahiro, Tsujitani, Shun-ichi, Koido, Shigeo, Nagai, Kazuhiro, Shimodaira, Shigetaka, Okamoto, Masato, Yonemitsu, Yoshikazu, Suzuki, Noboru, Nagaya, Masaki
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antigens
Bile Duct Neoplasms - immunology
Bile Duct Neoplasms - mortality
Bile Duct Neoplasms - therapy
Bile Ducts, Extrahepatic
Bile Ducts, Intrahepatic
Biliary Tract Neoplasms - immunology
Biliary Tract Neoplasms - mortality
Biliary Tract Neoplasms - therapy
Cancer therapies
Cancer Vaccines - therapeutic use
Chemotherapy
Cholangiocarcinoma - immunology
Cholangiocarcinoma - mortality
Cholangiocarcinoma - therapy
Clinical trials
Dendritic cells
Dendritic Cells - immunology
Female
Gallbladder Neoplasms - immunology
Gallbladder Neoplasms - mortality
Gallbladder Neoplasms - therapy
Gastroenterology
Hospitals
Humans
Immunotherapy
Immunotherapy, Active - methods
Male
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Mucin-1 - immunology
Original Article
Peptides
Prostate cancer
Retrospective Studies
Surgery
Survival Analysis
Treatment Outcome
WT1 Proteins - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). Methods Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined. Results No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level
ISSN:1091-255X
1873-4626
DOI:10.1007/s11605-013-2286-2